Health TrialsbyHealthPanel

Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS

ConditionPolycystic Ovarian Syndrome
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age20-40
SponsorPeking University Third Hospital

About this trial

This study will be carried out under the guidance of professional doctor, patients with PCOS will be treated with Sitagliptin or BeiDouGen capsule or both two to assess their ovarian function and reproductive outcomes, and compare the effect of different treatment methods, which will provide the basis for PCOS intervention strategy and related research

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female patients aged 20-40 years who plan to conceive or are infertile in our center.

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • Sitagliptin

    Drug

    100 mg QD for 3 month

  • BeiDouGen

    Drug

    60 mg BID for 3 month

  • Sitagliptin+BeiDouGen

    Drug

    100 mg Sitagliptin QD plus BeiDouGen 60 mg BID for 3 month

Treatment groups

300 Participants
are divided into 3 treatment groups
Group A: SitagliptinOther 1 intervention
Group B: BeiDouGenOther 1 intervention
Group C: Sitagliptin+BeiDouGenOther 1 intervention

Trial outcomes

Primary outcomes

1

Clinical pregnancy rate

the pregnancy situation among volunteers

Time frame
through study completion, an average of 2 year

Secondary outcomes

1

DHEA

dehydroepiandrosteron in serum during menstruation period

Time frame
before and after intervention（3 month）
2

total testosterone

total testosterone in serum during menstruation period

Time frame
before and after intervention（3 month）
3

FAI

Free testosterone index calculated by total testosterone and SHBG

Time frame
before and after intervention（3 month）
4

LH/FSH

the rate between LH and FSH

Time frame
before and after intervention（3 month）

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Peking University Third Hospital

Lead sponsor

Source ClinicalTrials.gov
Apply now